Nature Communications (Apr 2019)
Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions
- Jennifer E. Beane,
- Sarah A. Mazzilli,
- Joshua D. Campbell,
- Grant Duclos,
- Kostyantyn Krysan,
- Christopher Moy,
- Catalina Perdomo,
- Michael Schaffer,
- Gang Liu,
- Sherry Zhang,
- Hanqiao Liu,
- Jessica Vick,
- Samjot S. Dhillon,
- Suso J. Platero,
- Steven M. Dubinett,
- Christopher Stevenson,
- Mary E. Reid,
- Marc E. Lenburg,
- Avrum E. Spira
Affiliations
- Jennifer E. Beane
- Boston University School of Medicine
- Sarah A. Mazzilli
- Boston University School of Medicine
- Joshua D. Campbell
- Boston University School of Medicine
- Grant Duclos
- Boston University School of Medicine
- Kostyantyn Krysan
- David Geffen School of Medicine at UCLA
- Christopher Moy
- Johnson and Johnson Innovation
- Catalina Perdomo
- Princeton University
- Michael Schaffer
- Johnson and Johnson Innovation
- Gang Liu
- Boston University School of Medicine
- Sherry Zhang
- Boston University School of Medicine
- Hanqiao Liu
- Boston University School of Medicine
- Jessica Vick
- Boston University School of Medicine
- Samjot S. Dhillon
- Kaiser Permanente, Roseville and Sacramento
- Suso J. Platero
- Covance
- Steven M. Dubinett
- David Geffen School of Medicine at UCLA
- Christopher Stevenson
- Janssen Research and Development
- Mary E. Reid
- Roswell Park Comprehensive Cancer Center
- Marc E. Lenburg
- Boston University School of Medicine
- Avrum E. Spira
- Boston University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-019-09834-2
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 13
Abstract
Bronchial premalignant lesions can potentially progress to lung squamous cell carcinoma. Here, the authors profile bronchial biopsies from high-risk smokers by RNA sequencing and identify four molecular subtypes of premalignant lesions and an immune molecular signature that associates with lesion progression.
